Access cutting-edge alzheimer disease treatment through this clinical trial at a research site in Oakland. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Oakland location
Preparing your pre-screening questions…
Access alzheimer disease specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related alzheimer disease treatment provided free
Check if you qualify for this alzheimer disease clinical trial in Oakland, CA
No-Cost Study Care
Local to Oakland
Convenient for CA residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
This study is to test LHP588 in persons who have mild to moderate Alzheimer's disease (AD) who have shown progressive mental decline in the last year and who have P. gingivalis (Pg) infection. P. gingivalis infection has been linked to the development of dementia. LHP588 is designed to target the P. gingivalis bacterium, to potentially help to halt or slow down the progression of AD and its symptoms. A saliva test will be done to determine P. gingivalis infection. Tests for AD include standard questionnaires such as MMSE and a blood test for pTau217. Treatment will be blinded, meaning the participant and the doctor will not know if the participant is receiving LHP588 or placebo. The total time for participation in the study may be up to 64 weeks. This includes a screening period (to ensure the participant is suitable for the study and the study is suitable for the participant) of up to 12 weeks, a treatment period of up to 48 weeks, and a safety follow-up period of 4 weeks after the last dose of the study drug to check the participant's overall health. Treatment is a once-a-day capsule. Caregiver participation is required. The study requires the participant to visit the study center (with the caregiver) at least 20 times within 64 weeks (this does not include any unplanned visits that may be recommended by the study doctor). In addition, the study doctor or clinic staff will contact the participant via phone at least 1 time.
Sponsor: Lighthouse Pharmaceuticals, Inc.
Yes, this clinical trial (NCT06847321) has an active research site in Oakland, CA that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for alzheimer disease treatment options in Oakland, CA, this clinical trial (NCT06847321) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Oakland research site is actively enrolling participants for this clinical trial. You'll receive care from experienced alzheimer disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all alzheimer disease clinical trials near you to find additional studies recruiting in your area.
See all alzheimers disease clinical trials recruiting in Oakland — not just this study.
Browse Alzheimers Disease Trials in Oakland →